COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study was written by Allsup, David;Howard, Dena;Emmerson, Jake;Hockaday, Anna;Rawstron, Andy;Oughton, Jamie B.;Bloor, Adrian;Phillips, David;Nathwani, Amit;Paneesha, Shankara;Turner, Deborah;Munir, Talha;Hillmen, Peter. And the article was included in British Journal of Haematology in 2021.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:
This study designed a COSMIC phase II randomized controlled trial (RCT) in relapsed chronic lymphocytic leukemia (CLL) to test whether high dose ofatumumab based chemoimmunotherapy (CIT) was sufficiently efficacious to be investigated in larger trials. Ofatumumab was given in combination with investigators choice of chemotherapy comprising six cycles of either fludarabine and cyclophosphamide (FC) or bendamustine (B). The treatment schedule for sOf-FC/B was FC or B in combination with ofatumumab 300 mg day 1 cycle 1, ofatumumab 1000 mg day 8 Cycle 1, ofatumumab 1000 mg day 1 cycles 2-6 and treatment schedule for megaOf-FC/B was FC or B in combination with ofatumumab 300 mg day 1 cycle 1, ofatumumab 2000 mg, days 8, 15, 22 cycle 1, ofatumumab 2000 mg days 1, 8, 15, 22 cycle 2, ofatumumab 2000 mg day 1 cycles 3-6. Observed toxicities were compatible with those known for FC, B and ofatumumab with no excess infusional reactions in megaOf treated participants. Neither sOf or megaOf in combination with FC or B, reached pre-specified endpoints in terms of rates of CR/CRi to warrant further investigation. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem